Skip to Main Content

Paper Details

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature
611
2021
Author NameAffiliation
Ankit SinhaMax-Planck Institute of Biochemistry
Ankit SinhaInstitute of Translational Cancer Research and Experimental Cancer Therapy, Technical University Munich
Arndt VogelHannover Medical School
Andrea SchietingerMemorial Sloan Kettering Cancer Center
Andrea Schietinger
Peter SchirmacherInstitute of Pathology, University Hospital Heidelberg
Lars ZenderUniversity Hospital Tubingen
Lars ZenderGerman Cancer Research Center (DKFZ)
Lars ZenderEberhard-Karls University of Tubingen
Ido AmitWeizmann Institute of Science
  • 1 - 10

Datasets

Release 1.2